Evidence map›Paper›PMID 39117410›Full record

ArticleBMJ open2024

Safety and efficacy of drug-eluting stents versus heparin-bonded stents in treatment of femoropopliteal peripheral artery disease: study protocol for a multicentre, prospective randomised controlled trial in China (ELITE trial).

Yuhan Qi, Huawei Zhang, Jichun Zhao, Ding Yuan, Jiarong Wang, Jinting Ge, Bin Huang, Chengxin Weng, Tiehao Wang

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuhan QiDivision of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, China.ORCID 0000-0003-4081-9064
Huawei ZhangDepartment of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
Jichun ZhaoDivision of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, China.ORCID 0000-0001-8185-1373
Ding YuanDivision of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, China.ORCID 0000-0001-8066-8155
Jiarong WangDivision of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, China.
Jinting GeDivision of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, China.
Bin HuangDivision of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, China.ORCID 0000-0003-4767-0629
Chengxin WengDivision of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, China tiehao.wang@wchscu.cn chengxin_weng@wchscu.cn.
Tiehao WangDivision of Vascular Surgery, Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, China tiehao.wang@wchscu.cn chengxin_weng@wchscu.cn.ORCID 0000-0003-1607-3995

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEndovascular therapy has emerged as a prominent strategy for managing femoropopliteal peripheral artery disease, offering acceptable safety and efficacy compared with open surgical bypass. Both paclitaxel-eluting stents and heparin-bonded covered stents have exhibited enhanced clinical outcomes compared with bare metal stents. However, there is currently a lack of level I evidence comparing the safety and efficacy of paclitaxel-eluting stents and heparin-bonded covered stents. Therefore, the primary objective of this study is to systematically evaluate the efficacy and safety outcomes of these two types of stents. METHODS AND ANALYSIS: The ELITE trial is a prospective, multicentre, parallel, randomised controlled trial. A total of 450 patients will be recruited. The primary endpoints of the study include primary patency at 1 year post-index procedure. ETHICS AND DISSEMINATION: Ethical approval for this study was obtained from the Ethics Committee of West China Hospital of Sichuan University (approval number: 2023-1186). The results will be submitted to a major clinical journal for peer review and publication.

trial registrationELITE trial was registered on 27 September 2023 in the Chinese Clinical Trials Registry (ChiCTR2300076236).

Indexed as

Drug-Eluting StentsFemoral ArteryHeparinPeripheral Arterial DiseasePopliteal ArteryChinaEndovascular ProceduresFemaleHumansMaleMulticenter Studies as TopicPaclitaxelProspective StudiesRandomized Controlled Trials as TopicStentsTreatment OutcomeHeparinPaclitaxelAdult cardiologyRandomized Controlled TrialVASCULAR SURGERY

Identifiers

PMID39117410
PMCPMC11404165

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.